Wedbush Forecasts Strong Price Appreciation for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals (NASDAQ:DAWN) had its target price boosted by Wedbush from $29.00 to $30.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 149.58% from the stock’s current price.

A number of other equities research analysts also recently commented on DAWN. Needham & Company LLC cut their price objective on Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday. Piper Sandler lifted their target price on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. upped their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, November 7th. HC Wainwright decreased their price target on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.14.

Day One Biopharmaceuticals Trading Up 2.7%

NASDAQ:DAWN opened at $12.02 on Wednesday. The company has a 50-day moving average of $10.63 and a 200-day moving average of $8.74. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -7.91 and a beta of -1.26. Day One Biopharmaceuticals has a twelve month low of $5.64 and a twelve month high of $13.20.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The business had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. On average, research analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Michael Vasconcelles sold 2,728 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares of the company’s stock, valued at $51,005.20. This trade represents a 38.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Jeremy Bender sold 15,459 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $179,324.40. Following the sale, the chief executive officer directly owned 204,603 shares of the company’s stock, valued at approximately $2,373,394.80. The trade was a 7.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 36,461 shares of company stock worth $422,948. Insiders own 6.20% of the company’s stock.

Institutional Trading of Day One Biopharmaceuticals

Large investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in Day One Biopharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock worth $46,000 after purchasing an additional 1,029 shares during the period. Los Angeles Capital Management LLC lifted its position in shares of Day One Biopharmaceuticals by 1.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 100,314 shares of the company’s stock worth $935,000 after buying an additional 1,425 shares during the period. Perkins Capital Management Inc. boosted its stake in Day One Biopharmaceuticals by 2.1% in the 4th quarter. Perkins Capital Management Inc. now owns 84,000 shares of the company’s stock valued at $783,000 after buying an additional 1,750 shares in the last quarter. CWM LLC grew its position in Day One Biopharmaceuticals by 32.4% in the fourth quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after acquiring an additional 2,051 shares during the period. Finally, ProShare Advisors LLC grew its position in Day One Biopharmaceuticals by 12.9% in the second quarter. ProShare Advisors LLC now owns 18,545 shares of the company’s stock valued at $121,000 after acquiring an additional 2,121 shares during the period. Institutional investors own 87.95% of the company’s stock.

Key Stories Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Record revenue and revenue beat: Q4 product revenues and full‑year receipts accelerated (Q4 net product revenues reported at $52.8M; FY net product revenues $155.4M) and overall Q4 revenue of $53.72M topped analyst estimates. This top‑line strength is the main positive catalyst. Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
• Positive Sentiment: Reaffirmed and growth‑oriented 2026 guidance: management reiterated 2026 U.S. net product revenue guidance of $225–$250M and highlighted the Mersana acquisition (adds Emi‑Le into early clinical development), supporting a growth narrative beyond current OJEMDA™ sales. Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
• Neutral Sentiment: Investor materials and management commentary available: the earnings slide deck, press release and full earnings call/transcript were posted for deeper diligence — useful for assessing product adoption, gross margin trajectory and commercialization expenses but not immediate market drivers. View Press Release / Slide Deck
• Neutral Sentiment: Transcript coverage: multiple transcripts (Seeking Alpha, InsiderMonkey) provide Q&A details on commercial rollout, supply and competition; these are helpful for modeling but require parsing for any near‑term changes to guidance assumptions. Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS miss and continued losses: reported EPS was −$0.21, missing consensus (−$0.17); the company still shows negative net margins and ROE, which keeps profitability timelines uncertain and could constrain valuation multiples until quarters of sustained margin improvement arrive. Day One Biopharmaceuticals Q4 2025 Earnings Highlights

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.